Compare RNST & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | AAPG |
|---|---|---|
| Founded | 1904 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | N/A | 2025 |
| Metric | RNST | AAPG |
|---|---|---|
| Price | $36.34 | $30.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $43.17 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 484.8K | 5.1K |
| Earning Date | 10-28-2025 | 11-19-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $775,309,000.00 | $54,524,554.00 |
| Revenue This Year | $43.37 | N/A |
| Revenue Next Year | $13.13 | $368.64 |
| P/E Ratio | $19.79 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $26.97 | $16.50 |
| 52 Week High | $40.40 | $48.45 |
| Indicator | RNST | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 50.39 |
| Support Level | $35.16 | $30.00 |
| Resistance Level | $36.18 | $33.09 |
| Average True Range (ATR) | 0.80 | 0.83 |
| MACD | 0.25 | 0.14 |
| Stochastic Oscillator | 96.11 | 72.07 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.